Clinical Development

CRD-102 is currently undergoing phase 1b clinical trials, and has currently been administered to 18 patients. To date, the compound has been proven to be safe and effective in treating patients with advance heart failure, and has demonstrated excellent safety profile and also improvement in functional outcomes.

Initial discussions with the FDA at a pre-IND meeting has been positive. IND enabling trials are currently underway, and Cardiora anticipates that these will be completed by Q2 2016, and Cardiora intends to file an IND submission by Q4 2016.